cerebrolysin
Sign in to saveAlso known as FPE 1070, Cerebrolyzin, Cerebrolycin
Cerebrolysin (developmental code name FPF-1070) is an experimental mixture of enzymatically-treated peptides derived from pig brain whose constituents can include brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and ciliary neurotrophic factor (CNTF). Although it is under preliminary study for its potential to treat various brain diseases, it is used as a therapy in dozens of countries in Eurasia.
Key facts
- Drug.drug_name
- Cerebrolysin
- Drug.tradename
- 速利清
- Drug.CAS_number
- 12656-61-0
- Drug.DrugBank
- DB16599
- Drug.UNII
- 37KZM6S21G
- Drug.synonyms
- FPF-1070, 脑蛋白水解物 [cerebroprotein hydrolysate]
via Wikipedia infobox
Clinical Trials
40 registered- NAUNKNOWNA Prospective, Trial About Safety and Efficacy of Combined Treatment With Cerebrolysin in Acute Ischemic Hemispheric Stroke Patients Undergoing EndoVascular Treatment (EVT)Shaare Zedek Medical Center · NCT06070753
- PHASE4RECRUITINGEfficacy and Safety of Cerebrolysin on Prolonged Disorders of ConsciousnessKonkuk University Medical Center · NCT04427241
- UNKNOWNComparative Effectiveness of Neuroprotectants on Acute Ischemic Strokeyongjun wang · NCT01556854
- PHASE4COMPLETEDA Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular DementiaEver Neuro Pharma GmbH · NCT00947531
- COMPLETEDEvaluation of the Effect of Neuroprotective Drug on Treatment Result in Patients After Traumatic Brain InjuryPomeranian Medical University Szczecin · NCT05807503
- PHASE2/PHASE3COMPLETEDRandomized, Double-blind, Placebo-controlled Trial to Investigate Safety and Efficacy of Cerebrolysin™ in Patients With Aneurysmal Subarachnoid HemorrhageKwong Wah Hospital · NCT01787123
~3 min read
Encyclopedic overview
8 sectionsContents
- Research
- Stroke
- Dementia
- Other
- Adverse effects
- Pharmacology
- Regulatory
- References
Cerebrolysin (developmental code name FPF-1070) is an experimental mixture of enzymatically-treated peptides derived from pig brain whose constituents can include brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and ciliary neurotrophic factor (CNTF). Although it is under preliminary study for its potential to treat various brain diseases, it is used as a therapy in dozens of countries in Eurasia.
Cerebrolysin has been studied for potential treatment of several neurodegenerative diseases, with only preliminary research, as of 2023. No clear benefit in the treatment of acute stroke has been found, and an increased rate of spontaneous adverse effects requiring hospitalization is reported. Some positive effects have been reported when cerebrolysin is used to treat vascular dementia.
Excerpted from Wikipedia’s “cerebrolysin” article, available under the CC BY-SA 4.0 licence.